{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-087830","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2023-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.142045+00:00","generated_at":"2026-06-12T06:12:06.252173+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HOOKIPA Pharma receives Nasdaq bid price deficiency notice; has 180 days to regain compliance","bullets":["Received Nasdaq letter on Aug 3, 2023 due to closing bid price below $1.00 for 30 consecutive business days.","Non-compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on Global Select Market.","Automatic 180-day cure period until Jan 30, 2024; must have $1.00 closing bid for 10 consecutive days.","If still non-compliant by Jan 30, 2024, may qualify for a second 180-day period if certain requirements met.","Evaluating options including reverse stock split; stock continues trading under \"HOOK\" with no immediate effect."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-087830","json":"https://secwatch.observer/filing/0001104659-23-087830.json","markdown":"https://secwatch.observer/filing/0001104659-23-087830.md","text":"https://secwatch.observer/filing/0001104659-23-087830.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000110465923087830/0001104659-23-087830-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000110465923087830/tm2322899d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T06:12:06.252173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f0824dab8af2ca5cf6724bc447cbf0e48a8f1f2","claim":"HOOKIPA Pharma Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"PA Pharma Inc. (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the closing bid price of the Company’s common stock was below $1.00 per share for 30 consecutive business days, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. The notice from Nasdaq has no immediate effect on the listing of the Company’s common stock, and the common stock will continue to be listed on the Nasdaq Global Select Market under the s","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1760542/000110465923087830/0001104659-23-087830-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}